Event
ELRIG Drug Discovery 2026 | From Gene Perturbation to Phenotype
Katie Headland, Senior Director
Business Development UK
Fernanda Ricci,
Head, Advanced Cellular Assays
14–15 October 2026 | London, UK | Booth G06
How can we capture the complex cellular effects of gene perturbation in a human neuronal model?
At ELRIG Drug Discovery 2026, Axxam will explore this question through an approach that brings together human iPSC-derived motor neurons, Cell Painting and transcriptomic analysis.
On 15 October, Fernanda Ricci, Head of Advanced Cellular Assays at Axxam, will present how complementary morphological and molecular readouts can be integrated to investigate the effects of gene perturbation and generate a more comprehensive view of cellular phenotype.
Join Fernanda Ricci’s talk
From Gene Perturbation to Phenotype: Integrating Cell Painting and Transcriptomics in Human iPSC-Derived Motor Neurons
15 October 2026 | 11:25–11:55 | Auditorium 2
Understanding how gene perturbations translate into complex cellular phenotypes requires approaches that capture biological changes at multiple levels.
In her presentation, Fernanda will focus on an integrated strategy combining Cell Painting and transcriptomic profiling in human iPSC-derived motor neurons. By connecting high-content morphological phenotypes with gene expression data, these complementary readouts can provide deeper insight into the cellular consequences of gene perturbation.
The work illustrates how advanced cellular models, phenotypic profiling and molecular analysis can be combined to investigate complex biology and support early drug discovery.
Connecting gene perturbation with cellular phenotype
A single endpoint may capture only part of the biological response to a genetic perturbation. Combining complementary readouts can provide a broader picture of how cells respond at both morphological and molecular levels.
At Axxam, human iPSC-derived models can be integrated with technologies such as High-Content Imaging, Cell Painting, transcriptomics and functional assays to investigate complex cellular phenotypes.
This multiparametric approach can support target investigation and validation while providing biologically relevant data for early drug discovery programs.
Advanced cellular assays at Axxam
Axxam develops advanced cell-based models and assays to investigate complex disease biology and support drug discovery.
Our capabilities include human iPSC-derived cellular models, High-Content Imaging, Cell Painting, functional assays, electrophysiology and multi-omics approaches.
These technologies can be combined according to the biological question, from studying the consequences of gene perturbation to phenotypic screening and compound characterization.
Meet us at ELRIG Drug Discovery 2026
Fernanda will be joined in London by Katie Headland, Vice President BD & Sales Europe.
Visit Booth G06 to meet the Axxam team and discuss advanced cellular models, phenotypic approaches and your drug discovery programs.
14–15 October 2026
ExCeL London, UK
Booth G06
Meet the Axxam team at Booth G06